TNFRSF17 and Miyoshi myopathy: A study evaluating dual targeting of BCMA and G protein–coupled receptor, class C group 5 member D (GPRC5D) with CAR-T cell therapy showed it could mitigate BCMA escape-mediated relapse in a xenograft model of MM.